Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994784 · ClinicalTrials.gov registry record · Phase 2
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
A Phase 2 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02994784 is a Phase 2 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 27 participants.
The verdict
NCT02994784, a Phase 2 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a single arm, open label study designed to evaluate the safety and efficacy of propylene glycol-free melphalan hydrochloride in patients with AL amyloidosis. Treatment will be comprised of propylene glycol-free melphalan hydrochloride administered intravenously at a dose of 70-100 mg/m2/day on Days -3 and -2 as conditioning prior to autologous stem cell transplantation.
Interventions
- DRUG Propylene Glycol-Free Melphalan Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02994784
The ClinicalTrials.gov registry entry for NCT02994784 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Propylene Glycol-Free Melphalan Hydrochloride is the first listed.
NCT02994784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02994784 about?
NCT02994784 is a clinical study titled "Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients". This is a single arm, open label study designed to evaluate the safety and efficacy of propylene glycol-free melphalan hydrochloride in patients with AL amyloidosis. Treatment will be comprised of propylene glycol-free melphalan hydrochloride administered intravenously at a dose of 70-100 mg/m2/day ...
What is the current status of trial NCT02994784?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2018-01-08. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT02994784?
The interventions under investigation include: Propylene Glycol-Free Melphalan Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02994784?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.